Abstract：Objective: To investigate the effect of radioactive 125I particles in pancreatic cancer patients. Methods: 58 pancreatic cancer patients admitted n our hospital were selected and divided into the control group and the experiment group by order of medical treatment. The control group were treated by palliative operation and the experiment group were treated by CT guided radioactive 125I particles implantation. Two groups were both treated by conventional anti-inflammatory, analgesic, fluid replacement and other supporting symptomatic treatment after operation. The CEA, CA125, CA199, pain assessment, quality of life score, solid tumor curative effect and median survival time were compared before treatment and 1 month after treatment. Results: Compared with before treatment, the CEA, CA125 and CA199 level were lower (P<0.05), the experiment group were more obviously (P<0.05).Compared with before treatment, the VAS score were lower (P<0.05), the experiment group were more obviously (P<0.05) . Compared with the control group after treatment the tumor curative effect were better (P<0.05), the median survival time were longer(P<0.05) . Conclusion: Radioactive 125I particles can significantly reduce serum CEA, CA125 and CA199 levels in patients with pancreatic cancer, effectively alleviate the pain, improve clinical symptoms, improve the quality of life of patients, the tumor tissue has good killing effect, can effectively prolong the relative survival time of patients.
[1] Biankin A V, Waddell N, Kassahn K S, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes[J]. Nature, 2012, 491(7424): 399~405. [2] Roberts N J, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer[J]. Cancer discovery, 2012, 2(1): 41~46. [3] 王平,黄镇,崔彦.胰腺癌的早期诊断[J].肿瘤学杂志,2015,21(10):795~798. [4] Costa-Silva B, Aiello N M, Ocean A J, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver[J]. Nature Cell Biology, 2015, 17(6):816. [5] Zarogoulidis P, Pavlioglou P, Pivert P L, et al. Current and future intratumoral targeted treatment for pancreatic cancer[J]. Therapeutic delivery, 2014, 5(8): 913~926. [6] Xu J, Gattacceca F, Amiji M. Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice[J]. Molecular pharmaceutics, 2013, 10(5): 2031~2044. [7] Boj S F, Hwang C I, Baker L A, et al. Organoid models of human and mouse ductal pancreatic cancer[J]. Cell, 2015, 160(1-2):324~338. [8] Son J, Lyssiotis C A, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway[J]. Nature, 2013, 496(7443): 101~105. [9] Waddell N, Pajic M, Patch A M, et al. Whole genomes redefine the mutational landscape of pancreatic cancer[J]. Nature, 2015, 518(7540):495. [10] Jacobetz M A, Chan D S, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer[J]. Gut, 2013, 62(1): 112~120. [11] Frese K K, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer[J]. Cancer discovery, 2012, 2(3): 260~269.
2018, Vol. 24 
冀公网安备13080202000677号